RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

A UPMC pulmonologist discusses RSV, including what the symptoms are, who is most at risk and how effective the vaccine is.

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...

Clinicians and healthcare professionals should target adults aged 70 and over with underlying health conditions instead of the general population, when it comes to efforts to reduce spending and ...

As RSV approaches, some "real world" data out of France provides even more support for the RSV antibody shot for babies.

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

While RSV infections are known to cause major illness, especially in infants, the rate of infection increases with age. It ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

To understand the potential impact of RSV vaccinations, researchers created a model to assess the cost-effectiveness of vaccine programs in different age groups with different medical risk. Most ...